StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Chandan Taparia, Motilal Oswal

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byChandan Taparia, Motilal OswalHorizon: Intraday26 Oct 2026, 9:28 am ISTvia CNBC Awaaz.

Entry₹1,140.1Inferred
Target₹1,175
Total upside +3.06%
Stop loss₹1,118-1.94% risk
CMP₹1,148Just now
Active+0.69%+2.35%upside left 1h left
Follow Chandan Taparia for new calls(13% target hit, 72 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 12 other Intraday picks this session

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 26 Oct, 1:32 pm IST
5 supporting1 opposing
Supports the BUY call (5)

2 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·26 Oct · today

2 other SEBI-registered advisors have active intraday BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·26 Oct · today

Zydus Lifesciences' subsidiary Zylidac Bio has partnered with Prolific Machines to scale a biologics manufacturing platform to GMP production.

BSE · Company Update·21 Oct · 4d ago

(opens in new tab)

Zydus Lifesciences received USFDA approval for Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

BSE · Company Update·21 Oct · 5d ago

(opens in new tab)

Zydus Lifesciences received USFDA approval for its Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

NSE · Press Release·21 Oct · 5d ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

Zydus Lifesciences In Focus As US FDA Flags Data Integrity, Quality Control Issues At Gujarat Plant

NewsNdtv-Profit·26 Oct · today

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Chandan Taparia, Motilal Oswal

Every call and its outcome